Summary
Vertex Pharmaceuticals Inc. (VRTX) has filed an amendment to its Form 10-Q for the quarter ended June 30, 2011. This amendment primarily serves to file two exhibits with fewer redactions for which confidential treatment was previously requested, and to include updated officer certifications. The company states that this amendment does not update the disclosures to reflect events occurring after the original filing date of August 9, 2011. Investors should note that the core financial and operational information remains as previously reported, with the amendment focused on the public disclosure of previously confidential agreement details.
Financial Highlights
50 data pointsBeta
Financial Statements
Beta
| Revenue | $114.42M |
| Cost of Revenue | $5.40M |
| Gross Profit | $109.02M |
| R&D Expenses | $173.60M |
| SG&A Expenses | $96.66M |
| Operating Expenses | $280.31M |
| Operating Income | -$165.89M |
| Interest Expense | $6.96M |
| Net Income | -$174.07M |
| EPS (Basic) | $-0.85 |
| EPS (Diluted) | $-0.85 |
| Shares Outstanding (Basic) | 204.41M |
| Shares Outstanding (Diluted) | 204.41M |
Key Highlights
- 1Amendment No. 1 to the Form 10-Q for the quarter ended June 30, 2011, filed to provide less redacted versions of two exhibits.
- 2The amendment is for the sole purpose of filing exhibits for which confidential treatment was requested.
- 3Updated officer certifications are included in accordance with Rule 13a-14(a) of the Exchange Act.
- 4The amendment does not update disclosures for events occurring after the original filing date of August 9, 2011.
- 5Vertex Pharmaceuticals Inc. is a large accelerated filer.
- 6The company had 208,087,899 shares of common stock outstanding as of July 29, 2011.
- 7Key filed exhibits include a License and Collaboration Agreement with Alios BioPharma, Inc. and amendments to agreements with Cystic Fibrosis Foundation Therapeutics, Inc.